THROMBOCYTOPENIA
Curs an IV - limba engleza2012-2013
Background• 1/3 of all Hematology Consults in a General
Hospital are for thrombocytopenia
• 5 to 10% of all hospital patients are thrombocytopenic in the ICU the number increases to 35%
• Thrombocytopenic patients in the hospital suffer a twofold greater mortality rate than those who are not
Platelet Kinetics• Normal circulating platelet count
– 150.000 to 450.000/mmc in Northern Europeans– 90.000 to 300.000/mmc in people of
Mediterranean descent• 1/3 of platelets are sequestered in the spleen• Half life of a platelet is 9 to 10 days• Platelet production is the function of the
multinucleated megakaryocyte• 15.000 to 45.000 platelets are produced daily
to maintain steady state
Thrombopoietin (TPO)
• TPO is the primary regulatory protein in the production of platelets
• TPO gene is on chromosome 3• TPO is expressed in the liver, kidneys, and smooth
muscle cells• Has a plasma half life of 30 hours• The receptor for TPO is c-MPL which is present on
the megakaryocytes and platelets• TPO rises with platelet fall and declines as the
megakaryocyte and platelet mass increase
Thrombocytopenia – risk of bleeding
• The primary reason for evaluating thrombocytopenia is to assess the risk of bleeding and assess the presence of underlying disorders (TTP, HIT etc.)– < 20.000/mmc increased risk of bleeding– 20.000 – 50.000/mmc rarely have increase risk of
spontaneous bleeding but increase risk of bleeding from procedures
– 50.000 – 100.000/mmc no increased risk of spontaneous bleeding and can undergo most procedures
Thrombocytopenia - mechanisms
• Decreased production• Increased destruction• Increased consuption• Sequestration• Pseudothrombocytopenia
Pseudothrombocytopenia• Artifactually low platelet count due to in vitro
clumping of platelets• Usually caused by antibodies that bind platelets only
in presence of chelating agent (EDTA)• Seen in healthy individuals and in a variety of disease
states• Diagnosis:
Marked fluctuations in platelet count without apparent cause
Thrombocytopenia disproprotionate to symptoms Clumped platelets on blood smear Platelet count varies with different anticoagulants
Pseudothrombocytopenia
Platelet clumping in EDTA No clumping in heparin
Decreased Platelet Production• Marrow failure (pancytopenia)
aplastic anemia, chemotherapy, toxins• B-12, folate or (rarely) iron deficiency• Viral infection• Drugs that can selectively reduce platelet production
Alcohol Estrogens Thiazides Chlorpropamide Interferon
• Amegakaryocytic thrombocytopenia myelodysplasia (pre-leukemia) immune? (related to aplastic anemia)
• Cyclic thrombocytopenia (rare)• Inherited thrombocytopenia
Increased Platelet Consumption
• Intravascular coagulation (DIC or localized)
• Microangiopathy – TTP, Hemolytic-uremic sdr
• Damage by bacterial enzymes, etc
Thrombocytopenia and Infection• Immune complex-mediated platelet destruction
Childhood ITP Bacterial sepsis Hepatitis C, other viral infections
• Activation of coagulation cascade Sepsis with DIC
• Vascular/endothelial cell damage Viral hemorrhagic fevers Rocky Mountain Spotted Fever
• Damage to platelet membrane components by bacterial enzymes (eg, S pneumoniae sialidase)
• Decreased platelet production Viral infections (EBV, measles)
• Mixed production defect/immune consumption HIV infection
Immune Platelet Destruction• Autoimmune (ITP)
Childhood Adult
• Drug-induced Heparin Quinine, others
• Immune complex (infection, etc)• Alloimmune
Post-transfusion purpura Neonatal purpura
Idiopathic (Immune) Thrombocytopenic Purpura (ITP)
• Thrombocytopenia in the absence of other blood cell abnormalities (normal RBC & WBC, normal peripheral smear)
• No clinically apparent conditions or medications that can account for thrombocytopenia
ITP - Epidemiology
• ITP is a high prevalence disease 16 to 27 per million per year
• Incidence increases with age• Female predominance under the age of 60 but
not over the age of 60• It can have an abrupt onset or insidious onset.
It is generally abrupt in onset with children
ITP – Clinical forms• Childhood form (most < 10 yrs old)
May follow viral infection, vaccination Peak incidence in fall & winter ~50% receive some treatment ≥75% in remission within 6 mo
• Adult form No prodrome Chronic, recurrences common Spontaneous remission rate about 5%
ITP - Pathogenesis• Increased platelet destruction caused by
antiplatelet antibodies
• Lack of compensatory response by megakaryocytes due to suppressive effect of antiplatelet antibodies
• Pathogenesis was proved by Harrington when he infused himself with plasma from a women with ITP
05/06/2023 18
ITP - Pathogenesis• ITP plasma induces thrombocytopenia in normal
subjects• Platelet-reactive autoantibodies present in most cases
Often specific for a platelet membrane glycoprotein• Antibody coated platelets cleared by tissue
macrophages Most destruction in spleen (extravascular)
• Most subjects have compensatory increase in platelet production
• Impaired production in some patients Intramedullary destruction? Enhanced TPO clearance?
05/06/2023 19
ITP - Clinic• Abrupt onset (childhood ITP) / Gradual onset (adult ITP)• Common signs, symptoms, and precipitating factors include the
following:• Mucocutaneous bleeding
– Purpura – petechiae, echymosis– Menorrhagia, metrorrhagia– Epistaxis, gingival bleeding– Recent live virus immunization, recent viral illness
(childhood ITP)– Bruising tendency– GI bleed, CNS bleed = RARE
• Absence of constitutional symptoms or splenomegaly
ITP – Clinical manifestations
ITP – Clinical manifestations
ITP – Clinical manifestations
ITP - Diagnosis
• ITP is a Diagnosis of Exclusion
• No laboratory test can diagnose ITP
• Need to exclude other causes of thrombocytopenia
ITP - Associated Disorders• SLE• Antiphospholipid syndrome• CLL• Large granular lymphocyte syndrome• Autoimmune hemolytic anemia (Evans syndrome)• Common variable immune deficiency• Autoimmune lymphoproliferative disorder (ALPS)• Autoimmune thyroid disease• Sarcoidosis• Carcinomas• Lymphoma• H pylori infection• Following stem cell or organ transplantation• Following vaccination• HIV infection
Evaluation of Patient with Low Platelets
• History – Has the patient ever had a normal platelet count?– Carefully review medications, including OTC meds.
• Antibiotics, quinine, anti-seizure medications– Ask about other conditions which may be associated with low
platelets• Liver Disease/hepatitis• Thyroid Disease - both hypo- and hyper-• Infections: viral, rickettsial• Pregnancy
– Ask about other conditions which may be associated with ITP• Lupus, CLL, lymphoma
Evaluation of Patient with Low Platelets• Physical
– Evaluate for lymphadenopathy and splenomegaly– Look for stigmata of bleeding– Blood blisters and oral petechiae, ie “Wet Purpura”
• best harbinger of intracranial hemorrhage• Laboratory Data
– Other blood counts should be normal.– Check B12 and folate levels. – Look at peripheral smear to exclude pseudothrombocytopenia,
also exclude TTP (especially if anemia also present.)– Send coagulation screens (PT/PTT) to exclude DIC– Send HIV, hepatitis serologies and TSH
• Consider doing a bone marrow biopsy– Megakaryocytes should be present.
ITP - Evaluation• Features consistent with the diagnosis of ITP
– Thrombocytopenia with normal or slightly large platelets– Normal RBC morphology and number (may have
associated iron def or thallasemia etc.)– Normal white cell number and morphology– Splenomegaly rare
• Features not consistent with the diagnosis of ITP– Giant platelets– RBC abnormalities ie schisotocytes– Leukocytosis or Leukopenia
ITP - Laboratory evaluation
– Platelet associated immunoglobulin reflect plasma concentration and alpha granule concentration
– Bone Marrow not very helpful as initial test• May be helpful in patient over 50 years and concerned
about MDS• If patient has failed initial treatment and diagnosis is in
question
– TSH and HIV test helpful, Peripheral Smear helpful
ITP – Confirmatory Laboratory Testing
• Serum antiplatelet antibody assay (poor sensitivity)
• Test for specific anti-platelet glycoprotein antibodies (more specific, negative in 10-30%)
Confirmatory testing not necessary in typical cases
ITP- Principles of Management
• Most patients with ITP do not have clinically significant bleeding– Risk of intracranial bleed 0.1 to 1% (This is an
overestimate)– Wet Purpura ie epistaxis, gingival bleeding is a
risk factor for major bleeding• In asymptomatic patients with platelets counts
greater then 20 K observation is reasonable
ITP - Pharmacologic Management
• Steroids– Prednisone 1mg/kg/day with taper over 2 to 3
months– Decadron 40 mg/day x 4 days– Solumedrol 1 gram/day x 2 days
• Antibodies– IVIG 1 gram/day x 2 days– Anti-D 50 mcg/kg IV x1
ITP - Management
• Splenectomy– Immunize with Pneumovax, Hib, Meningococcal
• Chronic Anti-D therapy – Does not put the disease in remission
• Rituximab• Immunosuppressive treatment• AMG 531, Eltrombopag c-MPL agnonists• Observation
ITP – Glucocorticoid Therapy• Mechanism of action: Slows platelet destruction, reduces
autoantibody production
• Prednisone, 1-2 mg/kg/day (single daily dose)
• Begin slow taper after 2-4 weeks (if patient responds)
• Consider alternative therapy if no response within 3-4 weeks• About 2/3 of patients respond (plts > 50K) within 1 week
• Most patients relapse when steroids withdrawn
Advantages: high response rate, outpatient therapyDisadvantages: steroid toxicity (increases with time and dose), high
relapse rate
ITP - Management of Asymptomatic Adult
• If platelet count is >40.000-50.000/mmc, no therapy is required. Check platelet counts at designated intervals.
• If platelet count is < 20.000-30.000/mmc, begin therapy with corticosteroids.
• Stop all NSAIDS and ASA to improve platelet function.
ITP - Initial Management of Adult with Symptomatic Purpura
• If platelet count is >10.000/mmc, treat with prednisone alone - use 1 mg/kg.
• If platelet count <10.000/mmc, treat with prednisone, but also add IVIg 1g/kg/d x 2d. - may require admission
• Along with prednisone, add Calcium and Vitamin D to prevent bone loss.
• If patient has severe bleeding, may need platelet transfusions.
ITP - Subsequent Management of Adult with Symptomatic Purpura
• Follow platelet counts daily until >20, then can d/c patient with close follow-up
• Once platelet count normalizes, commence a slow steroid taper over 6-8 weeks.
• 1/3 of adults will have gone into remission.• 2/3 of patients will relapse during or after steroid
taper.
Management of Relapsed ITPSplenectomy
• Splenectomy is effective in 2/3 of patients, leading to normal platelet counts.
• Almost all responses occur within 7-10 days of splenectomy
• Can be performed via open method or laparoscopically.• Need to vaccinate against encapsulated bacteria 2 weeks
before procedure. • May need steroids and/or IVIg before procedure to boost
platelet counts preoperatively.• Operative mortality < 1%
• Indication: Steroid failure or relapse after steroid Rx (persistent severe thrombocytopenia or significant bleeding)
• Possible mechanisms of action: Slowed platelet consumption by Fc receptor blockade Accelerated autoantibody catabolism Reduced autoantibody production
• Dose: 0.4 g/kg/d x 5 days (alternative: 1 g/kg/d x 2 days)• About 75% response rate, usually within a few days to a week• Over 75% of responders return to pre-treatment levels within a
month
• Advantages: rapid acting, low toxicity
• Disadvantages: high cost, short duration of benefit, high relapse rate
• Indications: Lifethreatening bleeding; pre-operative correction of platelet count, steroids contraindicated or ineffective
Management of Relapsed ITP - Intravenous immunoglobulin therapy
Management of Refractory ITP• One third of patients will have an inadequate
response to splenectomy.• Management of these patients involves accepting that
they have a chronic, incurable condition.• Target platelet counts should be lower--aim for about
30.000/mmc or absence of bleeding.
Treatment of Refractory ITP
• Immunosuppressive agents– Rituximab (anti-CD20)– Mycophenolate mofetil– Cyclophosphamide– Vinca alkaloids
• Accessory splenectomy• Danazol• Colchicine• Eradication of H. pylori, if present• Adjunct agents
– Thrombopoietin Receptor Agonists• Romiplostim• Eltrombopag
05/06/2023 41
Special aspects
ITP and H Pylory• Up to 50% of patients with ITP and
concomitant H pylori infection improve after eradication of infection
• Confirm infection via breath test, stool antigen test or endoscopy
• Higher response rates in:• Patients from countries with high
background rates of infection • Patients with less severe thrombocytopenia
Thrombocytopenia and Pregnancy
• Benign thrombocytopenia of pregnancy Occurs in up to 5% of term pregnancies Accounts for about 75% of cases of
thrombocytopenia Asymptomatic, mild, occurs late in gestation
• Microangiopathy (Preeclampsia/eclampsia, HELLP)
• ITP (? increased incidence in pregnancy)
ITP In Pregnancy• Mild cases indistinguishable from gestational thrombocytopenia• Rule out eclampsia, HIV etc• Indications for treatment
platelets < 10.000/mmc platelets < 30.000/mmc in 2nd/3rd trimester, or with bleeding
• Treatment of choice is IVIg corticosteroids may cause gestational diabetes, fetal toxicity
• Splenectomy for severe, refractory disease some increased risk of preterm labor; technically difficult in 3rd
trimester• Potential for neonatal thrombocytopenia (approx 15% incidence)
consider fetal blood sampling in selected cases consider Cesarian delivery if fetal platelets < 20.000/mmc